Study Evaluating ABI-H2158-Containing Regimens in Chronic Hepatitis B Infection

Registry ID

EUCTR2019-004902-85

Source registry

EUCTR

Status

GB - no longer in EU/EEA

Phase

PHASE2

Sponsor

Assembly Biosciences

Start date

2020-08-11

Last update

2026-08-16

Conditions

• Chronic Hepatitis B Infection

Summary

- To evaluate the safety and tolerability of ABI-H2158 when administered in combination with Entecavir (ETV) in subjects with Chronic Hepatitis B Infection (CHB) - To evaluate the effect of ABI-H2158 in reducing hepatitis B virus (HBV) DNA in subjects with CHB

Locations

• , , UK

Related clinical trials

• A Phase I Clinical Study of AHB - 171 in Healthy Participants(HP) and Chronic Hepatitis B (CHB) Participants
• A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME)
• Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function
• A Study of SN2001 Dose, Safety & Immunogenicity in Healthy Adults

View on source registry